

CLINICAL TRIAL PROTOCOL

Open Access



Validation of a German version of the Cerebellar Cognitive Affective/ Schmahmann Syndrome Scale: preliminary version and study protocol

Andreas Thieme^{1*} , Sandra Roeske², Jennifer Faber^{2,3}, Patricia Sulzer^{4,5}, Martina Minnerop^{6,7,8}, Saskia Elben⁷, Heike Jacobi⁹, Kathrin Reetz^{10,11,12}, Imis Dogan^{10,11,12}, Miriam Barkhoff², Juergen Konczak¹³, Elke Wondzinski¹⁴, Mario Siebler¹⁴, Oliver Mueller^{15,16}, Ulrich Sure¹⁶, Jeremy D. Schmahmann¹⁷, Thomas Klockgether^{2,3}, Matthias Synofzik^{4,5} and Dagmar Timmann¹

Abstract

Background: Traditionally, cerebellar disorders including ataxias have been associated with deficits in motor control and motor learning. Since the 1980's growing evidence has emerged that cerebellar diseases also impede cognitive and affective processes such as executive and linguistic functions, visuospatial abilities and regulation of emotion and affect. This combination of non-motor symptoms has been named *Cerebellar Cognitive Affective/ Schmahmann Syndrome (CCAS)*. To date, diagnosis relies on non-standardized bedside cognitive examination and, if available, detailed neuropsychological test batteries. Recently, a short and easy applicable bedside test (CCAS Scale) has been developed to screen for CCAS. It has been validated in an US-American cohort of adults with cerebellar disorders and healthy controls. As yet, the CCAS Scale has only been available in American English. We present a German version of the scale and the study protocol of its ongoing validation in a German-speaking patient cohort.

Methods: A preliminary German version has been created from the original CCAS Scale using a standardized translation procedure. This version has been pre-tested in cerebellar patients and healthy controls including medical experts and laypersons to ensure that instructions are well understandable, and that no information has been lost or added during translation. This preliminary German version will be validated in a minimum of 65 patients with cerebellar disease and 65 matched healthy controls. We test whether selectivity and sensitivity of the German CCAS Scale is comparable to the original CCAS Scale using the same cut-off values for each of the test items, and the same pass/ fail criteria to determine the presence of CCAS. Furthermore, internal consistency, test-retest and interrater reliability will be evaluated. In addition, construct validity will be tested in a subset of patients and controls in whom detailed neuropsychological testing will be available. Secondary aims will be examination of possible correlations between clinical features (e.g. disease duration, clinical ataxia scores) and CCAS scores.

Perspective: The overall aim is to deliver a validated bedside test to screen for CCAS in German-speaking patients which can also be used in future natural history and therapeutic trials.

(Continued on next page)

* Correspondence: andreas.thieme@uk-essen.de

¹Department of Neurology, Essen University Hospital, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany
Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

(Continued from previous page)

Study registration: The study is registered at the German Clinical Study Register (DRKS-ID: [DRKS00016854](https://www.drks.org/DRKS00016854)).

Keywords: Affect, Cerebellum, Bedside test, Cognition, Human

Background

Cerebellar disease results in well-known motor performance deficits, including ataxia of stance and gait, limb incoordination, dysarthria, and oculomotor abnormalities. During the last decades, there has been growing evidence that cerebellar disease is not only accompanied by motor disturbances but also by cognitive and affective symptoms (see [1–3] for reviews). As early as 1998, Schmahmann and Sherman introduced the *Cerebellar Cognitive Affective/ Schmahmann Syndrome (CCAS)* [4]. The core symptoms of CCAS are difficulties with executive, linguistic and visuospatial functions as well as problems with the regulation of emotion and affect. Since its original description, evidence for the presence of CCAS has been accumulating in pediatric and adult patients suffering from different cerebellar diseases including various hereditary ataxias, cerebellar tumors, and cerebellar stroke [1–3]. In recent years, advances in structural and functional brain imaging allowed for detailed mapping of cognitive functions in the posterolateral cerebellar hemisphere [5–9]. As yet, diagnosis of CCAS relies on non-standardized bedside cognitive examination and, if available, detailed neuropsychological test batteries. Until recently, there has not been a validated bedside test that was able to reliably screen for CCAS in cerebellar patients – unlike well-established bedside tests for dementias or mild cognitive impairment (MCI), i.e. Mini Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA). However, MMSE and MoCA are of limited use to screen for CCAS because cerebellar patients frequently perform within the normal range [10]. Recently, Schmahmann and colleagues [10] have developed a bedside test designed to screen for CCAS in adults. In order to develop this CCAS Scale, they first applied a broad battery of 36 well-established neuropsychological tests in a large group of cerebellar patients primarily suffering from cerebellar degeneration. In the novel CCAS Scale, tests were implemented which captured the core cognitive domains of CCAS, distinguished best between cerebellar patients and controls, and at the same time were short and easy enough to be applied in a bedside setting. These include test items for semantic and phonemic fluency, category switching, verbal registration and delayed verbal recall, digit span forward and backward, cube draw and copy, similarities, go/ no-go, and affect. Single tests can either be passed reaching a specific cut-off score or failed. CCAS is considered possible if one test is failed, probable if two tests

are failed, and definite if three or more tests are failed. Version A of the CCAS Scale has then been validated in another US-American cohort of 39 adult cerebellar patients, including patients with cerebellar degeneration and focal cerebellar lesions and 55 matched healthy controls. It exhibited high values for selectivity [that is the ability to distinguish between patients and controls, or in other words preventing controls from being diagnosed as patients; possible/ probable/ definite CCAS: 78/ 93/ 100%] and reasonable sensitivity [that is the probability that a patient is identified as a patient; possible/ probable/ definite CCAS: 95/ 82/ 46%]. Furthermore, it showed modest internal consistency using Cronbach's alpha value (= 0.59) indicating that no test item within the scale measures the exact same domain(s) as another item. Thus, no test item is redundant. Comparing patients with pure cerebellar lesions and patients with additional extracerebellar involvement the authors found that difficulties in verbal registration and delayed verbal recall were more prominent in the latter. Therefore, poor performance in these two test items is indicative of extracerebellar involvement ("red flag"). In addition to the pass/ fail criteria which are used to screen for CCAS, a total sum score is calculated which allows for follow-up examinations in individual patients [10]. Three parallel versions B-D were developed to enable repeated assessments. In the present study preliminary German versions of the CCAS Scale are introduced, and the study protocol for their validation is presented.

Methods

Study aims

The first primary aim of this study was to create preliminary German versions of the CCAS Scale. The second primary aim will be their validation in a large cohort of patients with various cerebellar disorders and healthy age-, sex-, and education-matched controls. Secondary aims will be to examine possible relationships between clinical features such as disease duration or severity of cerebellar motor symptoms, and the CCAS score.

Study description and study design

Translation process of the original CCAS Scale into German language

A group of medical experts translated the original American English versions A-D of the CCAS Scale into German

accounting for language- (and cultural-) dependent differences while staying as close as possible to the original CCAS Scale. A standardized, six step procedure was used following guidelines for cross-cultural translation, adaptation, and validation of self-report measures, instruments, or scales for use in healthcare research [11, 12]. The expert group comprised three independent teams each consisting of two individuals (team 1: University Hospital and German Center for Neurodegenerative Diseases Bonn: S. Roeske = neuropsychologist, J. Faber = neurologist; team 2: University Hospital Essen: D. Timmann, A. Thieme = neurologists; team 3: University Hospital Tuebingen: P. Sulzer = neuropsychologist, M. Synofzik = neurologist).

Step 1: Each team translated the original CCAS Scales (A-D) independently to German. **Step 2:** For each version (A-D) a consensus version was derived. **Step 3:** Consensus version A was then translated back to American English by a bilingual expert (J. Konczak = neuroscientist). The parallel versions B-D were not translated back because instructions on the test form were similar in all versions. **Step 4:** Discrepancies were resolved in a joined discussion and a German prototype version A was formed. The senior author (J. D. Schmahmann) of the original CCAS Scale was involved in this step (and step 6, see below) to ensure that no information has been lost or added during the translation process. **Step 5:** The prototype version A was pretested in a small cohort of medical experts and laypersons. The medical expert group consisted of eleven neurologists, three neuropsychologists and one medical student (mean age: 33.8 ± 6.4 yrs.; age range: 23.8–49.0 yrs.; 6 males, 9 females; mean education: 19.6 ± 1.2 yrs.). None of them was involved in steps 1–4. The lay group consisted of 12 cerebellar patients, one healthy subject and three healthy first-degree relatives of patients with hereditary ataxias, i.e. persons at risk (mean age: 59.5 ± 14.9 ; age range: 23.4–84.0 yrs.; 8 males, 7 females; mean education: 15.2 ± 4.2 yrs.). All participants were asked to rate each item of the German prototype version A as “easy to understand”, “comprehensible”, “difficult to understand”, or “incomprehensible”. **Step 6:** Imprecise and misleading items were revised (for details see [Supplementary Materials](#), Part 2). The resulting preliminary version of the CCAS Scale, Version A, is shown in Fig. 1. The parallel versions were revised accordingly and are shown in [Supplementary Materials](#), Part 3.

There are also detailed test instructions for the examiner. Firstly, these instructions have been translated independently by each team, and next a consensus was derived (see [Supplementary Materials](#), Part 4).

Validation process

Inclusion and exclusion criteria To be eligible for the study, subjects must be 18 years or older, German-

speaking (primary language) and they must be able to understand and follow instructions and to give informed consent. Exclusion criteria comprise neurological or psychiatric disorders in control participants, and neurological disease other than cerebellar disease and primary psychiatric disorders in patients. Patients will be included who suffer from degenerative cerebellar disorders or focal cerebellar lesions (e.g. cerebellar stroke, tumor, or cerebellar surgical lesions). Alcohol or drug abuse, intake of centrally acting drugs (other than low dose antidepressants) and consuming diseases or general poor health are further exclusion criteria for all participants. Furthermore, participants under legal supervision will not be recruited. For detailed in- and exclusion criteria see Table 1.

Study sample For validation of version A at least 65 patients and an equal number of matched healthy controls will be recruited. About one third (≥ 25) of the patients will suffer from disorders that primarily affect the cerebellum (isolated cerebellar disease = cer-pure: 1. degenerative cerebellar disorders, e.g. spinocerebellar ataxia type 6 (SCA6); 2. focal cerebellar lesions, e.g. cerebellar stroke). The other two thirds (≥ 40 patients) will suffer from disorders with additional extracerebellar involvement (cerebellar plus disease = cer-plus: 1. degenerative cerebellar disorders, e.g. SCA1, 2 or 3; 2. focal cerebellar lesions, e.g. cerebellar stroke with additional involvement of the brain stem). Group assignment in patients with cerebellar degeneration goes by diagnosis: A genetic disease, which is known to involve extracerebellar regions, is considered a “cer-plus form”, although the clinical phenotype at the time of testing may be pure cerebellar.

An equivalent number of healthy matched participants will serve as controls. Each patient will be matched with a control participant of same sex, similar age (interval: ± 5 years) and similar years of education (intervals: < 9 yrs., 9–10 yrs., 11–13 yrs., 14–16 yrs., > 16 yrs.). We will use the same matching criteria as in [10] except for education matching because of the different educational systems in Germany and the United States.

Parallel versions B-D will be validated in groups of 25 patients (cer-pure and cer-plus, respectively) and 25 matched healthy controls each.

Patients in this investigator-initiated, multicenter study will be recruited from the ataxia clinics at the Departments of Neurology of the University Hospitals in Aachen, Bonn, Duesseldorf, Essen, Heidelberg and Tuebingen, as well as from the MediClin Fachklinik Rhein-Ruhr in Essen, and the Departments of Neurosurgery of the University Hospital in Essen and at the Klinikum Dortmund. Essen is the coordinating site. Furthermore, we will collaborate with the “Deutsche Heredo-Ataxie Gesellschaft e.V. (DHAG)”, a patient support group, and patients will be recruited via

[Note: The German CCAS Scale has not been validated yet, and especially the cut-off values may change.]

CEREBELLAR COGNITIVE AFFECTIVE /

SCHMAHMANN SYNDROME Skala (CCAS-Skala)

ID#:

Bildungsjahre:

VERSION 1A.

Datum:

Semantische Wortflüssigkeit	Punkte = alle korrekten Wörter (maximal 26 Wörter). „Nicht-Bestanden“ bei 15 Punkten oder weniger. (Nutzen Sie den Platz unten für Notizen.)	Punkte	Bestanden= 0 Nicht-Bestanden= 1																														
Bitte nennen Sie so viele Tiere oder Lebewesen wie Ihnen innerhalb einer Minute einfallen.		/26																															
Phonematische Wortflüssigkeit	Punkte = alle korrekten Wörter (maximal 19 Wörter). „Nicht-Bestanden“ bei 9 Punkten oder weniger. (Nutzen Sie den Platz unten für Notizen.)																																
Bitte nennen Sie so viele Wörter wie möglich mit dem Anfangsbuchstaben „F“ wie Ihnen innerhalb einer Minute einfallen. Benutzen Sie nicht Namen von Personen oder Orten und wiederholen Sie nicht dasselbe Wort in unterschiedlichen Formen. (Unterschiedliche Formen desselben Wortes sind z.B. „der Fisch, des Fisches, die Fische“)		/19																															
Kategorie-Wechsel	Punkte = Anzahl der korrekten Wechsel zwischen den Wortkategorien (maximal 15 Wechsel). Wiederholungen und Regelbrüche werden nicht bewertet. „Nicht-Bestanden“ bei 9 Punkten oder weniger. (Nutzen Sie den Platz unten für Notizen.)																																
Bitte nennen Sie eine Gemüsesorte und dann einen Beruf oder einen Job, dann eine andere Gemüsesorte und dann wieder einen weiteren Beruf usw. Wechseln Sie immer zwischen den beiden Kategorien ab. Nennen Sie so viele Wörter wie Ihnen innerhalb einer Minute einfallen.		/15																															
Verbales Lernen	Diese Aufgabe wird nicht mit Punkten bewertet. (Wenn 4 Versuche benötigt werden, die 5 Wörter zu lernen, ist dies ein Hinweis für eine zerebrale Beteiligung.)																																
Ich werde Ihnen nun eine Wortliste vorlesen, welche Sie bitte lernen sollen. Bitte wiederholen und merken Sie sich die Wörter. Ich werde Sie in einigen Minuten noch einmal bitten, diese Wörter wiederzugeben. (Lesen Sie die 5 Wörter in einer Geschwindigkeit von 1/Sekunde vor. Die Testperson wiederholt die Wörter einmal, dann wiederholt sie diese ein weiteres Mal. Wiederholen Sie die Wortliste bis die Testperson alle 5 Wörter erinnert. Brechen Sie nach 4 Versuchen ab.) <table border="1"> <thead> <tr> <th></th> <th>[Blume]</th> <th>[Frank]</th> <th>[Mut]</th> <th>[sprechen]</th> <th>[gelb]</th> </tr> </thead> <tbody> <tr> <td>Versuch 1</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> </tr> <tr> <td>Versuch 2</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> </tr> <tr> <td>Versuch 3</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> </tr> <tr> <td>Versuch 4</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> <td>[]</td> </tr> </tbody> </table>					[Blume]	[Frank]	[Mut]	[sprechen]	[gelb]	Versuch 1	[]	[]	[]	[]	[]	Versuch 2	[]	[]	[]	[]	[]	Versuch 3	[]	[]	[]	[]	[]	Versuch 4	[]	[]	[]	[]	[]
	[Blume]	[Frank]	[Mut]	[sprechen]	[gelb]																												
Versuch 1	[]	[]	[]	[]	[]																												
Versuch 2	[]	[]	[]	[]	[]																												
Versuch 3	[]	[]	[]	[]	[]																												
Versuch 4	[]	[]	[]	[]	[]																												
Zahlenspanne Vorwärts	Punkte = längste korrekt wiederholte Zahlenspanne. „Nicht-Bestanden“ bei 5 Punkten oder weniger.																																
Ich werde Ihnen nun einige Zahlen jeweils einmal vorlesen. Bitte wiederholen Sie diese in der exakt gleichen Reihenfolge. (Lesen Sie die Zahlen in einer Geschwindigkeit von 1/Sekunde laut vor. Beginnen Sie beim * und führen Sie die vorherigen Zahlenspannen nur durch, wenn * falsch wiedergegeben wurde.) <table border="1"> <tbody> <tr> <td>5-9</td> <td>[]</td> <td>4-8-7-0*</td> <td>[]</td> <td>3-0-1-2-6-4</td> <td>[]</td> <td>2-0-5-6-9-7-3-8</td> <td>[]</td> </tr> <tr> <td>2-1-3</td> <td>[]</td> <td>1-6-9-2-5</td> <td>[]</td> <td>7-3-1-9-8-4-6</td> <td>[]</td> <td></td> <td></td> </tr> </tbody> </table>				5-9	[]	4-8-7-0*	[]	3-0-1-2-6-4	[]	2-0-5-6-9-7-3-8	[]	2-1-3	[]	1-6-9-2-5	[]	7-3-1-9-8-4-6	[]																
5-9	[]	4-8-7-0*	[]	3-0-1-2-6-4	[]	2-0-5-6-9-7-3-8	[]																										
2-1-3	[]	1-6-9-2-5	[]	7-3-1-9-8-4-6	[]																												
Zahlenspanne Rückwärts	Punkte = längste korrekt wiedergegebene Zahlenspanne. „Nicht-Bestanden“ bei 3 Punkten oder weniger. Können 2 Ziffern nicht korrekt rückwärts wiedergegeben werden, werden 0 Punkte vergeben.																																
Nun geben Sie die Zahlen bitte rückwärts wieder, also in umgekehrter Reihenfolge. (Machen Sie das Beispiel vor, dann beginnen Sie beim *.) Bsp.: 5-8 = 8-5 *6-1 [] 3-8-2 [] 4-7-0-9 [] 6-5-2-8-1 [] 5-9-0-3-7-4 []																																	
Würfel (Zeichnen)	Punkte = 15 Punkte, wenn 12 Linien gezeichnet wurden und die Zeichnung dreidimensional ist. Hat die Zeichnung nicht 12 Linien oder ist nicht dreidimensional, führen Sie die Aufgabe „Würfel (Abzeichnen)“ durch.																																
Bitte zeichnen Sie einen sechsseitigen Würfel. Zeichnen Sie ihn transparent, also durchsichtig. (Nutzen Sie den Platz auf Seite 2.)																																	
Würfel (Abzeichnen)	Punkte = 12 Punkte, 1 Punkt pro Linie. Ziehen Sie jeweils 1 Punkt ab, wenn die Zeichnung nicht dreidimensional ist, 1 Punkt für jede Linie, die nicht gezeichnet wurde und 1 Punkt für jede zusätzlich gezeichnete Linie > 12. „Nicht-Bestanden“ bei 11 Punkten oder weniger.																																
Bitte zeichnen Sie den Würfel ab, der auf Seite 4 abgebildet ist. (Sorgfalt/Genauigkeit wird nicht bewertet.)																																	

Notizen:

Semantische WF	Phonematische WF	Kategorie-Wechsel

Fig. 1 Preliminary German CCAS Scale, Version A

[Note: The German CCAS Scale has not been validated yet, and especially the cut-off values may change.]

Zeichnen Sie den Würfel hier.




Fig. 1 *Continued*

[Note: The German CCAS Scale has not been validated yet, and especially the cut-off values may change.]


Verbaler Abruf	Spontan = 3 Punkte pro Wort, Kategorie = 2 Punkte, Mehrfachauswahl = 1 Punkt. Punkte = Gesamtpunktzahl. „Nicht-Bestanden“ bei 10 Punkten oder weniger. Wird nicht mehr als ein Wort bei der Mehrfachauswahl erinnert, ist dies ein Hinweis für eine zerebrale Beteiligung.	Punkte	Bestanden= 0 Nicht-Bestanden= 1
Wie lauten die Wörter, die ich Sie vor einer Weile gebeten habe, zu lernen? (Die Testperson gibt die Wörter, die sie sich vorher merken sollte, wieder. Benutzen Sie die Hinweise und die Mehrfachauswahl (unten), wenn notwendig.)			
	[Blume] [Frank] [Mut] [sprechen] [gelb]		
Spontane Wiedergabe	[] [] [] [] []		
Mit Hinweis	[] [] [] [] []		
Mit Mehrfachauswahl	[] [] [] [] []	/15	
Gemeinsamkeiten Korrekte Antwort (konzeptuell) = 2 Punkte, teilweise korrekte Antwort (konkret) = 1 Punkt, inkorrekte/ keine Antwort = 0 Punkte. Punkte = Gesamtpunktzahl. „Nicht-Bestanden“ bei 6 Punkten oder weniger. Auswertungshilfe – unten und in der Durchführungsanleitung.			
Was haben die folgenden Wörter gemeinsam? Was ist ihre Gemeinsamkeit? (Geben Sie ein Beispiel, testen Sie danach die Items.)			
Bsp.: Ball/Mond = rund	1.Nase/Ohr 2.Schaf/Elefant 3.See/Fluss 4.Flugzeug/Motorrad		
	[/2] [/2] [/2] [/2]	/8	
Go/No-Go 2 Punkte für keinen Fehler, 1 Punkt für 1 Fehler, 0 Punkte für 2 oder mehr Fehler. Punkte = Gesamtpunktzahl. „Nicht-Bestanden“ bei 0 Punkten.			
Ich werde nun auf den Tisch klopfen. Wenn ich einmal klopfe, heben Sie bitte den Finger und senken Sie ihn wieder! Wenn ich zweimal klopfe, machen Sie bitte nichts! (Geben Sie ein Beispiel für jede Bedingung, um sicherzugehen, dass die Testperson die Anweisung verstanden hat.)			
1 – 1 – 1 – 2 – 2 – 1 – 2 – 2 – 2 – 1 – 2 – 1 – 2 – 1			
		/2	
Affekt Geben Sie 6 Punkte, wenn keine Auffälligkeiten vorliegen. Ziehen Sie 1 Punkt pro vorhandenes Item ab. „Nicht-Bestanden“ bei 4 Punkten oder weniger. (Der Testleiter schätzt ein, ob die folgenden Auffälligkeiten vorliegen, Eindrücke von der Testperson oder deren engen Bezugspersonen werden miteinbezogen.)			
☐ Hat Schwierigkeiten die Aufmerksamkeit zu fokussieren oder bei der mentalen Flexibilität ☐ Emotional labil, unpassende/inkongruente Emotionen, erscheint hoffnungslos oder depressiv ☐ Zeigt schnell Zeichen einer Reizüberflutung oder ausweichendes Verhalten ☐ Äußert unlogische Gedanken oder Paranoia ☐ Zeigt fehlende Empathie, ist apathisch oder zeigt eine Affektverarmung ☐ Ist zornig oder aggressiv, reizbar, konfrontativ, hat Schwierigkeiten mit sozialen Grenzen oder sozialen Regeln/Normen			
		/6	
GESAMTWERT		/120	/10
Berechnen Sie den Gesamtwert (1. Spalte) und den Gesamtwert der „Nicht-Bestanden“ Aufgaben (2. Spalte). 1 „Nicht-Bestandene“ Aufgabe = mögliches CCAS; 2 „Nicht-Bestandene“ Aufgaben = wahrscheinliches CCAS; 3 oder mehr „Nicht-Bestandene“ Aufgaben = definitives CCAS.			

Hinweise und Mehrfachauswahl für die Aufgabe „Verbaler Abruf“					
Testwort	Blume	Frank	Mut	sprechen	gelb
Hinweis	wächst im Garten	Männernamen	Eigenschaft oder Tugend	Art der Kommunikation	Farbe
Mehrfachauswahl	Baum	Thomas	Tapferkeit	sprechen	rot
	Busch	Michael	Mut	reden	grün
	Blume	Andreas	Ehrlichkeit	singen	blau
	Gras	Frank	Geduld	rufen	gelb


Gemeinsamkeiten	Korrekte konzeptuelle Antwort (Beispiele)	Teilweise korrekte/konkrete Antwort (Beispiele)
Nase/Ohr	Sinnesorgane	Gesicht, Körperteil
Schaf/Elefant	Tiere, Säugetiere	Beine, Schwänze
See/Fluss	Gewässer	nass, kalt, schwimmen
Flugzeug/Motorrad	Transport-/ Verkehrsmittel	braucht Treibstoff, man kann sie steuern

Fig. 1 Continued

[Note: The German CCAS Scale has not been validated yet, and especially the cut-off values may change.]



Zeichnen Sie den Würfel hierhin ab.



Hoche, Guell, Vangel, Sherman, Schmahmann, Ataxia Center, Cognitive Behavioral Neurology Unit, Schmahmann Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital.
© 2016 The General Hospital Corporation. All Rights Reserved.

Fig. 1 *Continued*

Table 1 Inclusion and exclusion criteria for patient and control selection

Group	Inclusion criteria	Exclusion criteria
General	- Age $\geq$ 18 years - German-speaking (primary language) - Informed consent	- Alcohol or drug abuse - Intake of centrally acting drugs (other than low-dose antidepressants) - Consuming diseases - Poor health condition - Persons under legal supervision
Patients	- General inclusion criteria	- General exclusion criteria
Degenerative Cerebellar Disorders		- Severe primary psychiatric disorders
Cer-pure Disorders primarily affecting the cerebellum	- SAOA - EA1 and EA2 - SCA6 - SCA8 - SCA14 - ANO10 - Post-inflammatory cerebellar degeneration	
Cer-plus Disorders with relevant extracerebellar involvement	- MSA-C - all other hereditary ataxias including: SCA1, 2, 3, Friedreich's ataxia, early onset cerebellar ataxias	
Focal Cerebellar Lesions		
Cer-pure/ cer-plus	- Cerebellar stroke - Cerebellar hemorrhage - Cerebellar tumor - Cerebellar surgical lesion	
Controls	- General inclusion criteria	- General exclusion criteria - Neurological and psychiatric disorders
Pretesting Subjects	- General inclusion criteria	- General exclusion criteria - Neurologists and psychologists that were involved in the development of the German CCAS Scales

Abbreviations: *Cer-pure* Isolated Cerebellar Disease/ Lesion, *Cer-plus* Cerebellar Plus Disease/ Lesion, *SAOA* Sporadic Adult Onset Ataxia, *EA1* Episodic Ataxia Type 1, *EA2* Episodic Ataxia Type 2, *SCA1, 2, 3, 6, 8, 14* Spinocerebellar Ataxia Type 1, 2, 3, 6, 8, 14, *ANO10* Spinocerebellar Ataxia, Autosomal-Recessive Type 10, *MSA-C* Multisystem Atrophy Cerebellar Type, *CCAS* Cerebellar Cognitive Affective/ Schmahmann Syndrome

their newsletter and webpage. Healthy controls will be recruited from patients' families and by public bulletins.

Demographics and clinical assessment of cerebellar motor syndrome Demographics including years of education and employment, educational achievements as well as occupational and marital status will be recorded. For patients, medical records and available brain scans will be evaluated. Age of onset, disease duration and in case of genetically proven nucleotide repeat diseases the repeat length will be documented. Furthermore, a detailed medical history will be taken, and a neurological examination will be performed in every participant. Severity of cerebellar ataxia in patients will be evaluated using different clinical ataxia scales: The Scale for the Assessment and Rating of Ataxia (SARA) [13] will be used because of its widespread use. In addition, the International Cooperative Ataxia Rating Scale (ICARS) [14] will be used because it includes rating of cerebellar oculomotor deficits. Its short form – BARS – [15] will be used to enable direct comparison with the original US-American validation study. The SpinoCerebellar Ataxia Functional Index (SCAFI) [16] will be assessed because it allows for a more objective quantification of

motor deficits. Finally, non-ataxia signs will be assessed semi-quantitatively using the Inventory of Non-Ataxia Signs (INAS) [17].

Assessment of the CCAS Scale The CCAS Scale will be administered in each participant at least once. In the validation process of version A, at least 40 patients and 40 controls will receive a follow-up examination with the same version of the scale to determine test-retest and interrater reliability (≥ 20 patients and ≥ 20 controls, respectively). Retesting will be done with the same version because equivalence of versions A-D has not yet been shown (see [10] and Supplements). Follow-up will take place within an interval of 14 to 56 days. A time interval is favored instead of a fixed time span between test and retest (e.g. exactly 14 days) to control for learning effects by correlating retest results with different retest time intervals.

To assess construct validity of the German version of the CCAS Scale a detailed neuropsychological testing will be done in a subset of patients ($n \geq 20$) and controls ($n \geq 20$) using well-established neuropsychological test batteries available in German. These will comprise the logical memory test (part I and II) of the Wechsler Memory Scale – 4th edition (WMS-IV) [18], the copy immediate and delayed

recall of the Rey–Osterrieth Complex Figure Test (ROCF) [19], and the letter-number sequencing task of the WAIS-IV [20]. These tests measure the same cognitive domains as corresponding items of the CCAS Scale. Furthermore, the German version 3 of the MoCA [21] will be assessed for direct comparison with the CCAS Scale. Finally, the Patient Health Questionnaire (PHQ-9) [22] and the German version of the EuroQuol – 5 dimension – 3 level (EQ-5D-3L) questionnaire [23] will be administered.

Validation of parallel versions of the CCAS Scale will be done the same way as for validation of parallel German versions of the MoCA [21]. Each parallel version (B/C/D) of the CCAS Scale will be tested against version A. Testing of version B/C/D and version A will be done on the same day, with the order being randomized between participants.

Data analysis Selectivity and sensitivity will be assessed using the same cut-off values for individual test items, and the same three pass/ fail criteria determined in the original study by Hoche et al. [10] (that is: possible CCAS = one test failed; probable CCAS = two tests failed; definite CCAS = three or more tests failed). To assess selectivity the percentage of true negatives will be calculated, that is the percentage of controls which have been correctly identified as controls [number of controls identified as controls/ true number of controls in the sample * 100]. To assess sensitivity the percentage of true positives will be calculated, that is the percentage of patients which have been correctly identified as patients [number of patients identified as patients/ true number of patients in the sample * 100]. In case selectivity and sensitivity falls below the values of the original CCAS Scale, selectivity and sensitivity of individual tests will be assessed. Cut-off values of single test items and/ or cut-offs defining (possible/ probable/ definite) CCAS will be adjusted to achieve high selectivity and reasonable sensitivity – comparable to the values of the original CCAS Scale.

Differences between patient groups (pure cerebellar disease vs. patients with additional extracerebellar involvement) will also be analyzed. We want to verify that difficulties in verbal registration and delayed verbal recall are indicative of extracerebellar involvement (“red flags”). In further accordance with Hoche et al. [10], Cronbach’s alpha will be used to assess the inter-relatedness of the individual test items, i.e. internal consistency.

To study construct validity of the CCAS Scale subtests of validated German versions of neuropsychological test batteries will be used as the external criterion. We will compare the percentage of patients diagnosed with CCAS based on a detailed neuropsychological test battery with the percentage of patients identified by the CCAS Scale.

Finally, correlations between age, disease duration, severity of cerebellar motor symptoms (measured by clinical ataxia scores), and total CCAS sum score will be calculated.

All raw data (thus total number of failed tests respective total sum score and sub scores on single test items) will be tested for normal distribution using Kolmogorov-Smirnov tests. Parametric or non-parametric tests will be applied depending on distribution and final sample size.

Perspective

Clinical ataxia scales have been validated to rate the severity of motor symptoms in cerebellar disease [13–17], but so far there has not been a validated clinical scale to screen for the presence of the Cerebellar Cognitive Affective/ Schmahmann Syndrome (CCAS), and quantify CCAS severity. Only recently, Schmahmann and collaborators have developed and validated a promising screening tool for the CCAS – the CCAS Scale – for an American English-speaking population [10]. Till now, no validated German versions of the scale exist. German versions of the CCAS Scale are highly desirable to screen for the presence of CCAS in a clinical setting, but also for patient characterization and stratification in future therapeutical trials. The CCAS sum score may also serve as a therapeutic marker, but this would need future studies to show its sensitivity to change, and if this would be the case, its treatment responsiveness. In this multicenter study, four parallel versions (A-D) of the German CCAS Scale will be validated in a large cohort of German-speaking patients with cerebellar disorders. The parallel versions will allow multiple testing without practice effects.

The primary aim of our validation study is to show high selectivity, that is to show that the German versions of the scale are able to differentiate between patients and controls. We will test whether the pass/ fail criteria used to determine the presence of CCAS in the original scale also apply for the German scale. Cut-off values of individual test items and the pass/ fail criteria shown in Fig. 1 are taken from the US-American original and may change depending on findings in the German validation cohort. Furthermore, future studies are needed to test for possible age effects, and the need for age-dependent cut-off values and pass/ fail criteria. After full validation of the scale the implementation of a web-based training tool is planned.

We are interested whether the scale is able to screen for CCAS in patients with degenerative diseases, but also suffering from cerebellar stroke or surgical lesions due to cerebellar tumors. In the validation study of the original American English CCAS Scale only few patients with focal cerebellar lesions were tested [10]. In part of the patients with focal lesions brain MRI scans will be available. This will allow to map dysfunction in the different cognitive domains to lesions in specific cerebellar regions. For example, we expect that language dysfunction is associated with lesions of the right posterolateral cerebellar hemisphere, and visuospatial disabilities with lesions of the left posterolateral cerebellar hemisphere [6].

A limitation of the CCAS Scale is that detection of the neuropsychiatric abnormalities highly depends on the examiner's expertise. The authors of the US-American original were aware of this weakness and gave this item ("Affect") a weak denominator for the total sum score [10]. Additionally, administration of more detailed scales of neuropsychiatric dysfunction are recommended [24]. In future studies, expert neuropsychiatric assessments would be of interest as a further external criterion. Furthermore, testing of construct validity has some limitations. We will perform detailed neuropsychological testing only in a subset of patients. More importantly, although the core symptoms of CCAS are well described, as yet there are no standard criteria to diagnose CCAS based on detailed neuropsychological testing. Another approach to test construct validity would be to compare CCAS scores in patients with cerebellar diseases and patients with non-cerebellar neurological diseases in the future. Despite these limitations the CCAS Scale has been shown to be more sensitive to detect cognitive and affective changes in cerebellar disease than the Mini-Mental State Examination and the Montreal Cognitive Assessment [10]. The validated German CCAS Scale will allow trained healthcare personnel to screen for cognitive and affective symptoms in patients with cerebellar diseases in German-speaking countries.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s42466-020-00071-3>.

Additional file 1.

Abbreviations

ADHD: Attention Deficit Hyperactivity Disorder; ANO10: Spinocerebellar Ataxia, Autosomal-Recessive Type 10; BARS: Brief Ataxia Rating Scale; CCAS: Cerebellar Cognitive Affective/ Schmahmann Syndrome; CNRS: Cerebellar Neuropsychiatric Rating Scale; DFG: Deutsche Forschungsgemeinschaft; D-KEFS: Delis-Kaplan Executive Function System; DRKS: Deutsches Register Klinischer Studien; EA1/2: Episodic Ataxia Type 1/2; Eng.: English; EQ-5D-3L: EuroQuol – 5 Dimension – 3 Level Questionnaire; Fig.: Figure; Ger.: German; ICARS: International Cooperative Ataxia Rating Scale; ID: Identity; INAS: Inventory of Non-Ataxia Signs; MCI: Mild cognitive impairment; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; MSA-C: Multisystem Atrophy Cerebellar Type; PHQ-9: Patient Health Questionnaire (Depression Part); ROCFT: Rey–Osterrieth Complex Figure Test; SARA: Scale for the Assessment and Rating of Ataxia; SCAFI: SpinoCerebellar Ataxia Functional Index; SAOA: Sporadic Adult Onset Ataxia; SCA1/2/3/6/8/14: Spinocerebellar Ataxia Type 1/2/3/6/8/14; Tab.: Table; UMEA: University Medicine Essen Clinician Scientist Academy; US (–American): United States (American); vs.: Versus; WAIS-IV: Wechsler Adult Intelligence Scale – 4th edition; yrs.: Years; WMS-IV: Wechsler Memory Scale – 4th edition

Acknowledgements

The authors thank Raquel Van der Veen helping with data processing and study coordination. We are also very grateful to all patients and healthy subjects who participated in this study.

Authors' contributions

AT, DT, SR, JF, PS, MSy, JK, JDS and TK initiated the study, created the study concept and the German versions of the CCAS Scale. AT is the coordinating investigator. AT, DT, SR, JF, PS, MSy and JK made substantial contributions to the conception and the study design and wrote the study protocol or preceding research proposals for funding. KR, ID, MM, SE, MB, EW and MSi made contributions to the study protocol or research proposals and revised the final manuscript for medical content. AT and DT drafted the manuscript. AT, DT, SR and PS developed the statistical concept and performed the sample size calculation. AT has the main responsibility for statistical analyses and supervised parts of the protocol development. AT and DT contributed decisively to approval to ethics authorities. All authors read and approved the final manuscript.

Authors' information

Not applicable.

Funding

This investigator-initiated study is funded in part by a grant of the German Heredo-Ataxia Society (Deutsche Heredo-Ataxie-Gesellschaft e.V.) and a scholarship of UMEA/ DFG (University Medicine Essen Clinician Scientist Academy – a program funded by Deutsche Forschungsgemeinschaft; FU356/12–1) awarded to AT. The funders had no influence on the design of protocol, and will not have any impact on patient recruitment, data generation, statistical analyses or writing of the final manuscript.

Availability of data and materials

The datasets used to analyse the pretesting experiment are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study has been approved by the responsible ethics committee in Essen (local ethics number: 18–8444-BO) as well as the ethics committees in Aachen, Bonn, Duesseldorf and Tuebingen. It has been submitted to the ethics committee in Heidelberg.

All eligible patients and healthy control subjects who agree to participate in the study will be provided with a full verbal explanation of the study and the information sheet. After information is provided all participants will have enough time to consider participation before they are asked whether they are willing to take part in the study. Written informed consent will be given before any study specific procedures start. The study is conducted in accordance with the Declaration of Helsinki. It has been registered at the German Clinical Study Register (DRKS-ID: [DRKS00016854](https://www.drks.org/DRKS00016854)).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Neurology, Essen University Hospital, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. ²German Center for Neurodegenerative Diseases (DZNE) Bonn, Helmholtz Association, Venusberg-Campus 1, 53127 Bonn, Germany. ³Department of Neurology, Bonn University Hospital, Rheinische Friedrich-Wilhelms University Bonn, Venusberg-Campus 1, 53127 Bonn, Germany. ⁴Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, Eberhard Karls University Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. ⁵German Center for Neurodegenerative Diseases (DZNE) Tuebingen, Helmholtz Association, Otfried-Mueller-Straße 23, 72076 Tuebingen, Germany. ⁶Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Wilhelm-Johnen-Str., 52425 Juelich, Germany. ⁷Department of Neurology, Center for Movement Disorders and Neuromodulation, Medical Faculty, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany. ⁸Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany. ⁹Department of Neurology, Heidelberg University Hospital, Ruprecht-Karls University Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. ¹⁰Institute of Neuroscience and Medicine (INM-11), Research Centre Juelich,

Wilhelm-Johnen-Str., 52425 Juelich, Germany. ¹¹Department of Neurology, Aachen University Hospital, Rheinisch-Westfaelische Technische Hochschule Aachen (RWTH), Pauwelsstr. 30, 52074 Aachen, Germany. ¹²JARA-BRAIN Institute, Molecular Neuroscience and Neuroimaging, Research Centre Juelich, Wilhelm-Johnen-Str., 52425 Juelich, Germany. ¹³School of Kinesiology, University of Minnesota, 400 Cooke Hall 1900 University Ave S E, Minneapolis, MN 55455, USA. ¹⁴Department of Neurology and Neurorehabilitation, MediClin Fachklinik Rhein/ Ruhr, Auf der Roetsch 2, 45219 Essen, Germany. ¹⁵Present Address: Department of Neurosurgery, Klinikum Dortmund, Muensterstr. 240, 44145 Dortmund, Germany. ¹⁶Department of Neurosurgery, Essen University Hospital, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. ¹⁷Department of Neurology, Ataxia Center, Cognitive Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

Received: 13 January 2020 Accepted: 1 June 2020

Published online: 29 September 2020

References

- Adamaszek, M., D'Agata, F., Ferrucci, R., Habas, C., Keulen, S., Kirkby, K. C., Leggio, M., Marien, P., Molinari, M., Moulton, E., Orsi, L., Van Overwalle, F., Papadelis, C., Priori, A., Sacchetti, B., Schutter, D. J., Styliadis, C., & Verhoeven, J. (2017). Consensus paper: Cerebellum and emotion. *Cerebellum*, 16(2), 552–576. <https://doi.org/10.1007/s12311-016-0815-8>.
- Kozio, L. F., Budding, D., Andreasen, N., D'Arrigo, S., Bulgheroni, S., Imamizu, H., Ito, M., Manto, M., Marvel, C., Parker, K., Pezzulo, G., Ramnani, N., Riva, D., Schmahmann, J., Vandervort, L., & Yamazaki, T. (2014). Consensus paper: The cerebellum's role in movement and cognition. *Cerebellum*, 13(1), 151–177. <https://doi.org/10.1007/s12311-013-0511-x>.
- Marien, P., Ackermann, H., Adamaszek, M., Barwood, C. H., Beaton, A., Desmond, J., De Witte, E., Fawcett, A. J., Hertrich, I., Kueper, M., Leggio, M., Marvel, C., Molinari, M., Murdoch, B. E., Nicolson, R. I., Schmahmann, J. D., Stoodley, C. J., Thuerling, M., Timmann, D., Wouters, E., & Ziegler, W. (2014). Consensus paper: Language and the cerebellum: An ongoing enigma. *Cerebellum*, 13(3), 386–410. <https://doi.org/10.1007/s12311-013-0540-5>.
- Schmahmann, J. D., & Sherman, J. C. (1998). The cerebellar cognitive affective syndrome. *Brain*, 121, 561–579. <https://doi.org/10.1093/brain/121.4.561>.
- King, M., Hernandez-Castillo, C. R., Poldrack, R. A., Ivry, R. B., & Diedrichsen, J. (2019). Functional boundaries in the human cerebellum revealed by a multi-domain task battery. *Nature Neuroscience*, 22(8), 1371–1378. <https://doi.org/10.1038/s41593-019-0436-x>.
- Stoodley, C. J., MacMore, J. P., Makris, N., Sherman, J. C., & Schmahmann, J. D. (2016). Location of lesion determines motor vs. cognitive consequences in patients with cerebellar stroke. *NeuroImage: Clinical*, 12, 765–775. <https://doi.org/10.1016/j.nicl.2016.10.013>.
- Kansal, K., Yang, Z., Fishman, A. M., Sair, H. I., Ying, S. H., Jedynak, B. M., Prince, J. L., & Onyike, C. U. (2017). Structural cerebellar correlates of cognitive and motor dysfunctions in cerebellar degeneration. *Brain*, 140(3), 707–720. <https://doi.org/10.1093/brain/aww327>.
- Diedrichsen, J., King, M., Hernandez-Castillo, C., Sereno, M., & Ivry, R. B. (2019). Universal transform or multiple functionality? Understanding the contribution of the human cerebellum across task domains. *Neuron*, 102(5), 918–928. <https://doi.org/10.1016/j.neuron.2019.04.021>.
- Guell, X., Gabrieli, J. D. E., & Schmahmann, J. D. (2018). Triple representation of language, working memory, social and emotion processing in the cerebellum: Convergent evidence from task and seed-based resting-state fMRI analyses in a single large cohort. *Neuroimage*, 172, 437–449. <https://doi.org/10.1016/j.neuroimage.2018.01.082>.
- Hoche, F., Guell, X., Vangel, M. G., Sherman, J. C., & Schmahmann, J. D. (2018). The cerebellar cognitive affective/Schmahmann syndrome scale. *Brain*, 141(1), 248–270. <https://doi.org/10.1093/brain/aww317>.
- Beaton, D. E., Bombardier, C., Guillemin, F., & Ferraz, M. B. (2000). Guidelines for the process of cross-cultural adaptation of self-report measures. *Spine*, 25(24), 3186–3191. <https://doi.org/10.1097/00007632-200012150-00014>.
- Sousa, V. D., & Rojjanasirirak, W. (2011). Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: A clear and user-friendly guideline. *Journal of Evaluation in Clinical Practice*, 17(2), 268–274. <https://doi.org/10.1111/j.1365-2753.2010.01434.x>.
- Schmitz-Huebsch, T., du Montcel, S. T., Baliko, L., Berciano, J., Boesch, S., Depondt, C., Giunti, P., Globas, C., Infante, J., Kang, J. S., Kremer, B., Mariotti, C., Melegh, B., Pandolfo, M., Rakowicz, M., Ribai, P., Rola, R., Schoels, L., Szymanski, S., van de Warrenburg, B. P., Durr, A., Klockgether, T., & Fancellu, R. (2006). Scale for the assessment and rating of ataxia: Development of a new clinical scale. *Neurology*, 66(11), 1717–1720. <https://doi.org/10.1212/01.wnl.0000219042.60538.92>.
- Trouillas, P., Takayanagi, T., Hallett, M., Currier, R. D., Subramony, S. H., Wessel, K., Bryer, A., Diener, H. C., Massaquoi, S., Gomez, C. M., Coutinho, P., Hamida, M. B., Campanella, G., Filla, A., Schut, L., Timmann, D., Honnorat, J., Nighoghossian, N., & Manyam, B. (1997). International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. *Journal of the Neurological Sciences*, 145(2), 205–211. <https://doi.org/10.1111/j.1365-2125.2008.03158.x>.
- Schmahmann, J. D., Gardner, R., MacMore, J., & Vangel, M. G. (2009). Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. *Movement Disorders*, 24(12), 1820–1828. <https://doi.org/10.1002/mds.22681>.
- Schmitz-Huebsch, T., Giunti, P., Stephenson, D. A., Globas, C., Baliko, L., Sacca, F., Mariotti, C., Rakowicz, M., Szymanski, S., Infante, J., van de Warrenburg, B. P., Timmann, D., Fancellu, R., Rola, R., Depondt, C., Schoels, L., Zdzienicka, E., Kang, J. S., Dohlinger, S., Kremer, B., Melegh, B., Filla, A., & Klockgether, T. (2008). SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia. *Neurology*, 71(7), 486–492. <https://doi.org/10.1212/01.wnl.0000324863.76290.19>.
- Jacobi, H., Rakowicz, M., Rola, R., Fancellu, R., Mariotti, C., Charles, P., Durr, A., Kueper, M., Timmann, D., Linnemann, C., Schoels, L., Kaut, O., Schaub, C., Filla, A., Baliko, L., Melegh, B., Kang, J. S., Giunti, P., van de Warrenburg, B. P., Fimmers, R., & Klockgether, T. (2013). Inventory of Non-Ataxia Signs (INAS): Validation of a new clinical assessment instrument. *Cerebellum*, 12(3), 418–428. <https://doi.org/10.1007/s12311-012-0421-3>.
- Lepach, A. C., & Petermann, F. (2012). Gedächtnisdiagnostik mit der Wechsler Memory Scale – Fourth edition. *Zeitschrift für Neuropsychologie*, 23(3), 123–132. <https://doi.org/10.1024/1016-264X/a000070>.
- Shin, M. S., Park, S. Y., Park, S. R., Seol, S. H., & Kwon, J. S. (2006). Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test. *Nature Protocols*, 1(2), 892–899. <https://doi.org/10.1038/nprot.2006.115>.
- Petermann, F. (2012). *Deutschsprachige adaptation der WAIS-IV von D. Wechsler*. Frankfurt: Pearson Assessment.
- Costa, A. S., Fimm, B., Friesen, P., Soundjock, H., Rottschy, C., Gross, T., Eitner, F., Reich, A., Schulz, J. B., Nasreddine, Z. S., & Reetz, K. (2012). Alternate-form reliability of the Montreal cognitive assessment screening test in a clinical setting. *Dementia and Geriatric Cognitive Disorders*, 33(6), 379–384. <https://doi.org/10.1159/000340006>.
- Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. *Journal of General Internal Medicine*, 16(9), 606–613. <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>.
- Rabin, R., Gudex, C., Selai, C., & Herdman, M. (2014). From translation to version management: A history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. *Value in Health*, 17(1), 70–76. <https://doi.org/10.1016/j.jval.2013.10.006>.
- Daly, M., Sherman, J. C., & Schmahmann, J. D. (2016). The cerebellar neuropsychiatric rating scale (CNRS): Development of a new assessment tool for the affective component of the CCAS (abstract). *The Journal of Neuropsychiatry and Clinical Neuroscience*, 28(3), 41–42. <https://doi.org/10.1176/appi.neuropsych.15080210>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.